Description

Pemetrexed Powder for Solution for Infusions 500 mg. №1 Vial

Ingredients:

Each vial contains 500 mg of Pemetrexed disodium hemipentahydrate.

Dosage:

The recommended dose of Pemetrexed for infusion is based on body surface area and should be administered under the supervision of a healthcare provider.

Indications:

Pemetrexed is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer and mesothelioma.

Contraindications:

Do not use Pemetrexed if you have a history of severe hypersensitivity reactions to Pemetrexed or any of its components.

Directions:

Pemetrexed should be reconstituted and diluted as per the instructions provided in the package insert before administration.

Scientific Evidence:

Pemetrexed is a multi-targeted antifolate that inhibits several enzymes involved in purine and pyrimidine synthesis, ultimately disrupting DNA and RNA production in cancer cells. Clinical trials have demonstrated the efficacy of Pemetrexed in improving progression-free survival and overall survival in patients with non-small cell lung cancer and mesothelioma.

Research published in the Journal of Clinical Oncology has shown that Pemetrexed in combination with cisplatin is superior to other regimens in terms of response rates and overall survival in patients with advanced non-squamous non-small cell lung cancer.

Additional Information:

Pemetrexed may cause myelosuppression, fatigue, gastrointestinal toxicities, and skin rash as common side effects. It is important to monitor blood counts regularly during treatment with Pemetrexed to manage potential toxicities effectively.

Patients should be advised to stay hydrated and take folic acid and vitamin B12 supplements to reduce the risk of certain side effects associated with Pemetrexed therapy.